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Table. Rates of Stent Thrombosis
Any post-PCI AC
for routine
prophylaxis
(N¼436)
No post-PCI AC for
routine
prophylaxis
(N¼1,009)
Adjusted
HR [95%
CI]
Adjusted
p-Value
Acute
(24 hour)
stent
thrombosis
3 (0.7) 10 (1.0) 0.65 [0.13,
3.18]
0.59
Thirty-day
stent
thrombosis
7 (1.7) 20 (2.1) 0.97 [0.37,
2.53]
0.95
Post-PCI AC for
routine
prophylaxis with
pre-PCI UFH
(N¼325)
Pre-PCI UFH with
no post-PCI AC for
routine prophylaxis
(N¼623)
Unadjusted
HR [95%
CI]
Unadjusted
p-Value
Acute
(24 hour)
stent
thrombosis
2 (0.6) 3 (0.5) 1.28 [0.21,
7.68]
0.78
Thirty-day
stent
thrombosis
5 (1.6) 8 (1.3) 1.20 [0.39,
3.65]
0.75
Only post-PCI AC
for routine
prophylaxis with
no pre-PCI UFH
(N¼111)
No pre-PCI UFH or
post-PCI AC for
routine prophylaxis
(N¼386)
Unadjusted
HR [95%
CI]
Unadjusted
p-Value
Acute
(24 hour)
stent
thrombosis
1 (0.9) 7 (1.9) 0.50 [0.06,
4.02]
0.50
Thirty-day
stent
thrombosis
2 (1.9) 12 (3.3) 0.57 [0.13,
2.55]
0.46
Values presented as n (%). Stent thrombosis was classiﬁed according to the Academic
Research Consortium deﬁnition of deﬁnite or probable. AC ¼ anticoagulation; PCI ¼ percu-
taneous coronary intervention; UFH ¼ unfractionated heparin.
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Intracoronary Bivalirudin Bolus During Primary Angioplasty Improves
Postprocedural Angiographic Flow and Myocardial Reperfusion Indexes
Alessandro Lupi1, Andrea Rognoni1, Gioel G. Secco2, Angelo S. Bongo1
1AOU Maggiore della Carità, Novara, Italy, 2University of Eastern Piedmont,
Novara, Italy
Background: Bivalirudin efﬁcacy in the very ﬁrst hours after primary PCI
has been questioned, due to increased acute stent thrombosis rates. Intracoronary
administration of the bivalirudin bolus might furnish an extremely high
local drug concentration without changing the global dose administered to the
patient, with a potential favorable effect over the pro-thrombotic milieu of the
infarct related artery. Thus we prospectively investigated the feasibility and
safety of intracoronary bivalirudin bolus administration during primary percuta-
neous coronary interventions (PCI), comparing it with the standard intravenous
route.
Methods: In 245 consecutive patients treated with primary PCI we administered
intracoronary bivalirudin bolus followed by standard intravenous infusion. Post-
procedural coronary blood ﬂow indexes and clinical reperfusion markers of these
patients were compared with a propensity score-matched cohort of primary PCI pa-
tients treated with standard intravenous bivalirudin bolus plus infusion.
Results: Our study suggests safety similar bleeding episodes were observed in the two
groups. However we observed better TIMI frame count values (14.7 vs 17.9,
P¼0.001), higher rates of  70% ST resolution (72.7 vs 60.0%, p¼0.004) and lower
postprocedural peak CK-MB levels (188.3  148.7 vs 242.1  208.1 Ui/dL,
P¼0.025) in the intracoronary bolus group. Acute stent thrombosis was observed only
in 3 cases, all in the intravenous bolus group (P¼NS). These results were substantially
conﬁrmed when the analysis was restricted to patients with evidence of an occluded
infarct related artery before PCI.
Conclusions: In the population studied intracoronary bivalirudin bolus during primary
PCI is safe and might improve results obtained through the standard intravenous route
over postprocedural coronary ﬂow and clinical myocardial reperfusion.B136 JACC Vol 64/11/Suppl B j September 13–1TCT-465
Safety and efﬁcacy of intracoronary bivalirudin administration during primary
angioplasty in comparison with a standard treatment with heparin and
provisional GP2b3a inhibitors
Alessandro Lupi1, Gioel G. Secco2, Andrea Rognoni1, Italo Porto3,
Maurizio Lazzero1, Angelo S. Bongo1
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Background: Bivalirudin efﬁcacy in the very ﬁrst hours after primary PCI has been
questioned, due to increased acute stent thrombosis rates. Intracoronary adminis-
tration of the bivalirudin bolus might furnish an extremely high local drug con-
centration without changing the global dose administered to the patient, with a
potential favorable effect over the pro-thrombotic milieu of the infarct related artery.
We prospectively investigated the feasibility and safety of intracoronary bivalirudin
bolus administration during primary percutaneous coronary interventions (PCI),
comparing this strategy with the standard treatment based upon unfractionated
heparin (UFH) with provisional GP2B3A inhibitors (GPI) given through the intra-
venous route.
Methods: In 273 consecutive patients treated with primary PCI we administered
intracoronary bivalirudin bolus followed by standard intravenous infusion.
Postprocedural coronary blood ﬂow indexes and clinical reperfusion markers of
these patients were compared with a propensity score-matched cohort of primary
PCI patients treated with standard treatment with intravenous UFH 70Ui/Kg
(eventually with supplementary boluses to achieve an ACT>250sec) plus pro-
visional GPI.
Results: In the intracoronary bivalirudin group we observed better TIMI frame count
values (14.86.5 vs 16.99.3, P¼0.002), higher rates of  70% ST resolution (72.1
vs 44.5%, p¼0.001), lower incidence of no-reﬂow (7.0 vs 13.5%, p< 0.011) and a
trend for lower postprocedural peak CK-MB levels (140.0 [53.7-235.5] vs 159.2
[64.3-269.9] Ui/dL, p¼0.06). Moreover acute stent thrombosis (< 24h after PCI) was
observed in 11 cases, all in the UFH/GPI group (p¼0.009). Intracoronary bivalirudin
administration was safe, with less internal bleedings (3.7 vs 11.2%, p¼0.001) and less
need for transfusion (4.6 vs 1.1, p¼0.012). The results were substantially conﬁrmed
when the analysis was restricted to patients with an occluded infarct related artery
before PCI.
Conclusions: In the population studied intracoronary bivalirudin during primary PCI
was safe and might improve postprocedural coronary ﬂow, clinical myocardial
reperfusion and acute stent thrombosis rates, in comparison with the UFH plus pro-
visional GPI treatment.
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Background: Bivalirudin has been shown to reduce bleeding complications and
improve clinical outcomes in percutaneous coronary interventions but has not been
well studied in peripheral arterial interventions (PAI). We sought to evaluate the ef-
ﬁcacy and safety of bivalirudin as compared with unfractionated heparin (UFH) in
patients undergoing PAI by evaluating in-hospital outcomes from a large, real-world,
US hospital database of over 600 hospitals.
Methods: We identiﬁed all patients (n¼23,934) entered from 1/08-12/12 in the
PREMIER hospital database following PPI of the extremities and who were treated
with bivalirudin or UFH. In-hospital outcomes that were compared according to
treatment included death , myocardial infarction (MI), transfusion, stroke, amputation,
Major Adverse Cardiac Events (MACE: death, MI, stroke or amputation) and Net
Adverse Cardiac Events (NACE: MACE and transfusion). Propensity score matching
(PSM) was performed to control for selection bias.
Results: In-hospital outcomes for both the unadjusted population and the 3,649 PSM
pairs are shown in the Table. After PSM, bivalirudin was still associated with
signiﬁcantly lower rates of death, transfusion, MACE and NACE compared with
UFH. Linear regression modeling conﬁrmed these ﬁndings. Subgroup analysis in the
PSM population showed consistent treatment effect for all outcomes among
subgroups.7, 2014 j TCT Abstracts/Pharmacotherapy - Procedural Anticoagulants
30-day Mortality in Patients with Early ST
Timing
of ST
Bivalirudin
(n¼2,889)
Heparin  GPI
(n¼2,911)
Relative risk
[95% CI] P-Value*
Acute (24
hrs)
1/36 (2.8%) 1/6 (16.7%) 0.17 [0.01,
2.16]
0.14
Subacute
(1-30d)
3/25 (12.0%) 15/34 (44.1%) 0.29 [0.10,
0.88]
0.01
Early
(30d)
4/60 (6.7%) 16/40 (40.0%) 0.19 [0.07,
0.52]
0.0002
*Cochran-Mantel-Haenszel c2 test stratiﬁed by study
Unadjusted population
p
PSM population
p
Bivalirudin
N ¼ 4370
UFH
N ¼
19,564
Bivalirudin
N ¼ 3649
UFH
N ¼
3649
% % % %
Death 0.3 1.0 <0.0001 0.3 0.7 0.01
Stroke 0.1 0.3 0.054 0.2 0.3 0.22
MI 0.6 1.2 0.0004 0.5 0.8 0.25
Amputation 1.3 4.5 <0.0001 1.5 2.0 0.09
Transfusion 3.4 10.0 <0.0001 4.0 5.3 0.009
MACE 2.2 6.6 <0.0001 2.3 3.5 0.003
NACE 5.4 14.8 <0.0001 5.9 7.9 0.0009
Association Between Activated Clotting Time (per 50 sec increase) and
Clinical Outcome
Unadjusted OR
(95% CI) p value
Adjusted OR
(95% CI)
p
value
In hospital overt
bleeding
0.94 (0.88, 1.01) 0.09 1.00 (0.93, 1.08) 0.96
In hospital death 0.79 (0.71, 0.88) <0.0001 1.01 (0.89, 1.15) 0.85
In hospital death/MI 0.98 (0.93, 1.04) 0.51 1.01 (0.95, 1.08) 0.77
1 year cardiac
death/MI
0.97 (0.93, 1.01) 0.16 1.00 (0.95, 1.04) 0.81
1 year cardiac
death/MI/TLR
0.97 (0.94, 1.00) 0.07 0.99 (0.96, 1.03) 0.57
Abbreviations: MI, myocardial infarction; TLR, target lesion revascularization
Models adjusted for age, sex, body mass index, hypertension, diabetes, heart failure, smoking,
cholesterol level, prior PCI/CABG, shock at presentation, MI at presentation, stent type (drug
eluting vs bare metal), glycoprotein IIb/IIIa use
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: This analysis from a very large US hospital database suggests that the
use of bivalirudin anticoagulation for PAI may confer signiﬁcant clinical beneﬁts over
heparin. These results require conﬁrmation in a prospective randomized trial.
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Background: Controversy exists regarding the optimal choice of anticoagulation
regimen for percutaneous coronary intervention (PCI). We performed a meta-analysis
of randomized controlled trials (RCT) to compare bivalirudin (bival) versus heparin
with provisional or routine glycoprotein IIb/IIIa inhibitor (GPI) use on 30-day out-
comes following PCI.
Methods: Medline/Pubmed and Cochrane CENTRAL were searched along with
recent abstract presentations at national meetings for all RCTs comparing BIV with
provisional GPI use versus heparin with provisional or routine GPI use for PCI.
Pooled estimates of 30 day outcomes were generated for with random-effect models to
compare the treatment groups. Data is presented as odds ratios (OR) [95% conﬁdence
intervals].
Results: Our analysis included 14 studies with 30,446 patients that were randomized
to either bivalirudin with provisional GPI use (n¼14,869) or heparin with provisional
GPI use (n¼6,451) or heparin with routine GPI use (n¼9,126). There was no sig-
niﬁcant difference between anticoagulation with bival compared with heparin for 30
day death (OR 0.94 [0.78-1.14]) or myocardial infarction (OR 1.11 [0.97-1.27]). Early
stent thrombosis was signiﬁcantly greater with bivalirudin compared with heparin (OR
1.62 [1.18-2.23], p¼0.003), especially when comparing bivalirudin versus heparin
with provisional GPI use (OR 2.09 [1.26-3.47], p¼0.005) or among STEMI patients
(OR 2.17 [1.15-4.10], p¼0.02). However, bivalirudin reduced the risk of major bleed
(OR 0.58 [0.49-0.69], p< 0.0001) and TIMI major bleeding (OR 0.58 [0.47-0.71], p<
0.0001) compared with heparin. Meta-regression analysis demonstrated that bleeding
risk with use of heparin signiﬁcantly increases with increasing GPI use (p¼0.02).
Conclusions: Meta-analysis of 14 RCTs with 30,446 patients demonstrated that
bivalirudin is associated with higher risk of stent thrombosis but lower risk of major
bleeding compared with heparin.
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Background: The risk of early (30 day) stent thrombosis (ST) is considerable after
primary PCI for STEMI. We sought to determine the independent predictors of early
ST and evaluate the risk of mortality after ST according to antithrombotic therapy
used during the index primary PCI.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/PhMethods: In a patient-level pooled analysis from the HORIZONS-AMI and EURO-
MAX trials, we studied 5,800 patients undergoing primary PCI at 188 sites, random-
ized to either bivalirudin or heparin a glycoprotein IIb/IIIa inhibitor (GPI). Predictors
of ST were determined by multivariate logistic regression, and 30-day mortality was
evaluated according to timing of ST and antithrombotic treatment received.
Results: Of 100 patients (1.7%) who developed early ST, 20 (20%) died within 30 days
of enrollment. By logistic regression, independent predictors of early ST were pre-PCI
TIMI grade ﬂow 0-1 and Killip class 2 at presentation. Bivalirudin was associated
with higher rates of early ST (2.1% vs. 1.4%, RR¼1.51, adj. p-value¼0.07) driven by a
higher incidence of acute ST (1.2% vs. 0.2%, RR¼6.04, p< 0.0001) with similar rates
of subacute ST (0.9% vs. 1.2%, RR¼0.74, p¼0.24) in comparison to heparin  GPI.
However, 30-day mortality rates among patients with ST were lower in the bivalirudin-
treated subset; this was consistent for both acute and subacute ST (Table). As a result,
only 4/2,889 bivalirudin-treated patients died within 30 days after early ST compared
to 16/2,911 heparin  GPI treated patients (0.14% vs. 0.56% respectively, P¼0.01).
Conclusions: Killip class 2 during acute MI presentation and pre-procedure TIMI
grade ﬂow 0-1 are independent predictors of early ST after primary PCI. Although the
risk of ST within 30 days is higher among patients treated with bivalirudin due to a
greater hazard of acute ST, death attributable to early ST is substantially less common
in patients having received bivalirudin compared to heparin  GPI.TCT-469
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Background: Monitoring the intensity of anticoagulation with heparin during
percutaneous coronary intervention (PCI) using the activated clotting time (ACT) is
one of the most frequently used tests in invasive cardiology. However, despite its
ubiquitous use, controversy remains regarding the association of ACT with ischemic
and bleeding events.
Methods: We reviewed all PCI procedures performed at Mayo Clinic (Rochester,
MN) between 2001 - 2012 and evaluated the association between the ACT value at the
time of PCI and in-hospital and 1-year outcomes. For descriptive purposes, ACT
values were grouped into tertiles. We used logistic and Cox proportional hazards
regression models to estimate the association of ACT, modeled continuously, with
outcomes while accounting for baseline characteristics.
Results: Of 12,059 patients studied, 3,978 (33.0%) had ACT < 227, 4,047 (33.6%) had
ACT227-285, and 4,034 (33.4%)hadACT>285.Groupswere similar regarding baseline
and procedural characteristics. In univariate analysis, ACT had associations with in-hos-
pital and 1-year clinical events; however, after multivariable adjustment, ACT at the time
of device activation was not independently associated with outcomes (Table).armacotherapy - Procedural Anticoagulants B137
